{"entity":"pfizer","id":"ent_pfizer","name":"Pfizer","from":"2025-11-10","to":"2026-11-10","page":"https://asof.is/record/pfizer/diff?from=2025-11-10&to=2026-11-10","summary":"Between 2025-11-10 and 2026-11-10, Pfizer's record changed in 14 facts: 2 replaced (net income $8.03 billion → $7.77 billion; revenue $63.63 billion → $62.58 billion), 6 added, 6 ended; 9 unchanged.","counts":{"changed":14,"added":6,"ended":6,"replaced":2,"unchanged":9,"skipped_posts":{"from":0,"to":0}},"by_predicate":[{"predicate":"cash_and_equivalents","added":1,"ended":1,"replaced":0,"unchanged":0},{"predicate":"quarterly_net_income","added":1,"ended":1,"replaced":0,"unchanged":0},{"predicate":"quarterly_revenue","added":1,"ended":1,"replaced":0,"unchanged":0},{"predicate":"shares_outstanding","added":1,"ended":1,"replaced":0,"unchanged":0},{"predicate":"total_assets","added":1,"ended":1,"replaced":0,"unchanged":0},{"predicate":"total_equity","added":1,"ended":1,"replaced":0,"unchanged":0},{"predicate":"net_income","added":0,"ended":0,"replaced":1,"unchanged":0},{"predicate":"revenue","added":0,"ended":0,"replaced":1,"unchanged":0},{"predicate":"chair","added":0,"ended":0,"replaced":0,"unchanged":1},{"predicate":"cik","added":0,"ended":0,"replaced":0,"unchanged":1},{"predicate":"fiscal_year_end","added":0,"ended":0,"replaced":0,"unchanged":1},{"predicate":"headquarters","added":0,"ended":0,"replaced":0,"unchanged":1},{"predicate":"listed_on","added":0,"ended":0,"replaced":0,"unchanged":1},{"predicate":"registrant_name","added":0,"ended":0,"replaced":0,"unchanged":1},{"predicate":"sic_industry","added":0,"ended":0,"replaced":0,"unchanged":1},{"predicate":"state_of_incorporation","added":0,"ended":0,"replaced":0,"unchanged":1},{"predicate":"ticker","added":0,"ended":0,"replaced":0,"unchanged":1}],"added":[{"id":"clm_23E72D4D980E","predicate":"cash_and_equivalents","value":"1,824,000,000 United States dollar","valid_from":"2026-09-27","valid_to":null,"published":"2026-11-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer cash and equivalents: 1,824,000,000 United States dollar\", as of 2026-09-27. Claim clm_23E72D4D980E, https://asof.is/claim/clm_23E72D4D980E, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800326000127/0000078003-26-000127-index.htm.","url":"https://asof.is/claim/clm_23E72D4D980E","accessed":"2026-11-10"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/78003/000007800326000127/0000078003-26-000127-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2026","published_at":"2026-11-03T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q3 FY2026, filed 2026-11-03"}},{"id":"clm_7B5F356BDB2E","predicate":"quarterly_net_income","value":"3,242,000,000 United States dollar","valid_from":"2026-09-27","valid_to":null,"published":"2026-11-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer quarterly net income: 3,242,000,000 United States dollar\", as of 2026-09-27. Claim clm_7B5F356BDB2E, https://asof.is/claim/clm_7B5F356BDB2E, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800326000127/0000078003-26-000127-index.htm.","url":"https://asof.is/claim/clm_7B5F356BDB2E","accessed":"2026-11-10"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/78003/000007800326000127/0000078003-26-000127-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2026","published_at":"2026-11-03T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q3 FY2026, filed 2026-11-03"}},{"id":"clm_F01F5C40574B","predicate":"quarterly_revenue","value":"16,583,000,000 United States dollar","valid_from":"2026-09-27","valid_to":null,"published":"2026-11-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer quarterly revenue: 16,583,000,000 United States dollar\", as of 2026-09-27. Claim clm_F01F5C40574B, https://asof.is/claim/clm_F01F5C40574B, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800326000127/0000078003-26-000127-index.htm.","url":"https://asof.is/claim/clm_F01F5C40574B","accessed":"2026-11-10"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/78003/000007800326000127/0000078003-26-000127-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2026","published_at":"2026-11-03T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q3 FY2026, filed 2026-11-03"}},{"id":"clm_7F37B9735E29","predicate":"shares_outstanding","value":"5,699,853,733 shares","valid_from":"2026-10-28","valid_to":null,"published":"2026-11-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer shares outstanding: 5,699,853,733 shares\", as of 2026-10-28. Claim clm_7F37B9735E29, https://asof.is/claim/clm_7F37B9735E29, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800326000127/0000078003-26-000127-index.htm.","url":"https://asof.is/claim/clm_7F37B9735E29","accessed":"2026-11-10"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/78003/000007800326000127/0000078003-26-000127-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2026","published_at":"2026-11-03T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q3 FY2026, filed 2026-11-03"}},{"id":"clm_E3BBF3297E77","predicate":"total_assets","value":"204,544,000,000 United States dollar","valid_from":"2026-09-27","valid_to":null,"published":"2026-11-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer total assets: 204,544,000,000 United States dollar\", as of 2026-09-27. Claim clm_E3BBF3297E77, https://asof.is/claim/clm_E3BBF3297E77, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800326000127/0000078003-26-000127-index.htm.","url":"https://asof.is/claim/clm_E3BBF3297E77","accessed":"2026-11-10"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/78003/000007800326000127/0000078003-26-000127-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2026","published_at":"2026-11-03T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q3 FY2026, filed 2026-11-03"}},{"id":"clm_84ED4CDADE9C","predicate":"total_equity","value":"89,001,000,000 United States dollar","valid_from":"2026-09-27","valid_to":null,"published":"2026-11-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer total equity: 89,001,000,000 United States dollar\", as of 2026-09-27. Claim clm_84ED4CDADE9C, https://asof.is/claim/clm_84ED4CDADE9C, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800326000127/0000078003-26-000127-index.htm.","url":"https://asof.is/claim/clm_84ED4CDADE9C","accessed":"2026-11-10"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/78003/000007800326000127/0000078003-26-000127-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2026","published_at":"2026-11-03T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q3 FY2026, filed 2026-11-03"}}],"ended":[{"id":"clm_7F3FCDE33BD4","predicate":"cash_and_equivalents","value":"1,343,000,000 United States dollar","valid_from":"2025-09-28","valid_to":"2025-12-31","published":"2025-11-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer cash and equivalents: 1,343,000,000 United States dollar\", as of 2025-09-28 (until 2025-12-31). Claim clm_7F3FCDE33BD4, https://asof.is/claim/clm_7F3FCDE33BD4, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800325000150/0000078003-25-000150-index.htm.","url":"https://asof.is/claim/clm_7F3FCDE33BD4","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_7D4C9A5A57B2","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/78003/000007800325000150/0000078003-25-000150-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2025","published_at":"2025-11-04T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q3 FY2025, filed 2025-11-04"}},{"id":"clm_FDB33475C290","predicate":"quarterly_net_income","value":"3,541,000,000 United States dollar","valid_from":"2025-09-28","valid_to":"2026-03-29","published":"2025-11-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer quarterly net income: 3,541,000,000 United States dollar\", as of 2025-09-28 (until 2026-03-29). Claim clm_FDB33475C290, https://asof.is/claim/clm_FDB33475C290, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800325000150/0000078003-25-000150-index.htm.","url":"https://asof.is/claim/clm_FDB33475C290","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_53B07B940F0E","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/78003/000007800325000150/0000078003-25-000150-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2025","published_at":"2025-11-04T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q3 FY2025, filed 2025-11-04"}},{"id":"clm_259CE7C5C459","predicate":"quarterly_revenue","value":"16,654,000,000 United States dollar","valid_from":"2025-09-28","valid_to":"2026-03-29","published":"2025-11-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer quarterly revenue: 16,654,000,000 United States dollar\", as of 2025-09-28 (until 2026-03-29). Claim clm_259CE7C5C459, https://asof.is/claim/clm_259CE7C5C459, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800325000150/0000078003-25-000150-index.htm.","url":"https://asof.is/claim/clm_259CE7C5C459","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_04BC67D14071","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/78003/000007800325000150/0000078003-25-000150-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2025","published_at":"2025-11-04T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q3 FY2025, filed 2025-11-04"}},{"id":"clm_5BDDB8D74479","predicate":"shares_outstanding","value":"5,685,707,552 shares","valid_from":"2025-10-29","valid_to":"2026-02-19","published":"2025-11-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer shares outstanding: 5,685,707,552 shares\", as of 2025-10-29 (until 2026-02-19). Claim clm_5BDDB8D74479, https://asof.is/claim/clm_5BDDB8D74479, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800325000150/0000078003-25-000150-index.htm.","url":"https://asof.is/claim/clm_5BDDB8D74479","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_51DCE9CF5E2B","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/78003/000007800325000150/0000078003-25-000150-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2025","published_at":"2025-11-04T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q3 FY2025, filed 2025-11-04"}},{"id":"clm_92D82FE1E9CA","predicate":"total_assets","value":"208,731,000,000 United States dollar","valid_from":"2025-09-28","valid_to":"2025-12-31","published":"2025-11-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer total assets: 208,731,000,000 United States dollar\", as of 2025-09-28 (until 2025-12-31). Claim clm_92D82FE1E9CA, https://asof.is/claim/clm_92D82FE1E9CA, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800325000150/0000078003-25-000150-index.htm.","url":"https://asof.is/claim/clm_92D82FE1E9CA","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_220B65364A06","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/78003/000007800325000150/0000078003-25-000150-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2025","published_at":"2025-11-04T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q3 FY2025, filed 2025-11-04"}},{"id":"clm_84E5FD850428","predicate":"total_equity","value":"92,801,000,000 United States dollar","valid_from":"2025-09-28","valid_to":"2025-12-31","published":"2025-11-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer total equity: 92,801,000,000 United States dollar\", as of 2025-09-28 (until 2025-12-31). Claim clm_84E5FD850428, https://asof.is/claim/clm_84E5FD850428, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800325000150/0000078003-25-000150-index.htm.","url":"https://asof.is/claim/clm_84E5FD850428","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_7F8BD7A5E4E8","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/78003/000007800325000150/0000078003-25-000150-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2025","published_at":"2025-11-04T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q3 FY2025, filed 2025-11-04"}}],"replaced":[{"predicate":"net_income","from":{"id":"clm_9E891C94D652","predicate":"net_income","value":"8,031,000,000 United States dollar","valid_from":"2024-12-31","valid_to":"2025-12-31","published":"2025-02-27","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer net income: 8,031,000,000 United States dollar\", as of 2024-12-31 (until 2025-12-31). Claim clm_9E891C94D652, https://asof.is/claim/clm_9E891C94D652, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/0000078003-25-000054-index.htm.","url":"https://asof.is/claim/clm_9E891C94D652","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_B68A9D81D6E4","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/0000078003-25-000054-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2024","published_at":"2025-02-27T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-K FY2024, filed 2025-02-27"}},"to":{"id":"clm_B68A9D81D6E4","predicate":"net_income","value":"7,771,000,000 United States dollar","valid_from":"2025-12-31","valid_to":null,"published":"2026-02-26","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer net income: 7,771,000,000 United States dollar\", as of 2025-12-31. Claim clm_B68A9D81D6E4, https://asof.is/claim/clm_B68A9D81D6E4, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800326000026/0000078003-26-000026-index.htm.","url":"https://asof.is/claim/clm_B68A9D81D6E4","accessed":"2026-11-10"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/78003/000007800326000026/0000078003-26-000026-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2025","published_at":"2026-02-26T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-K FY2025, filed 2026-02-26"}}},{"predicate":"revenue","from":{"id":"clm_0D26120DBD16","predicate":"revenue","value":"63,627,000,000 United States dollar","valid_from":"2024-12-31","valid_to":"2025-12-31","published":"2025-02-27","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer revenue: 63,627,000,000 United States dollar\", as of 2024-12-31 (until 2025-12-31). Claim clm_0D26120DBD16, https://asof.is/claim/clm_0D26120DBD16, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/0000078003-25-000054-index.htm.","url":"https://asof.is/claim/clm_0D26120DBD16","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_55A653F47AF3","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/0000078003-25-000054-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2024","published_at":"2025-02-27T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-K FY2024, filed 2025-02-27"}},"to":{"id":"clm_55A653F47AF3","predicate":"revenue","value":"62,579,000,000 United States dollar","valid_from":"2025-12-31","valid_to":null,"published":"2026-02-26","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer revenue: 62,579,000,000 United States dollar\", as of 2025-12-31. Claim clm_55A653F47AF3, https://asof.is/claim/clm_55A653F47AF3, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800326000026/0000078003-26-000026-index.htm.","url":"https://asof.is/claim/clm_55A653F47AF3","accessed":"2026-11-10"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/78003/000007800326000026/0000078003-26-000026-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2025","published_at":"2026-02-26T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-K FY2025, filed 2026-02-26"}}}],"rule":"Two states compared by claim id: in both, unchanged; only on to, added; only on from, ended. An ended and an added claim on one predicate are a replacement when the ended one points to the added (superseded_by), or the predicate has exactly one of each and the added begins the day the ended ends. Added rows are labelled for to, ended rows for from. Posts and Hugging Face repos are counted in skipped_posts, not listed.","legend":{"dates":"valid_from: when the claim took effect (a period figure: the day its period closed). published: the earliest day a source on the record published it (a filing's filing date, a post's date; null when no source carries one). recorded: the day AsOf first held it. A figure can take effect weeks before it is published.","citation":"citation: how to cite the row (plain: one sentence with the value, its as-of date, the claim id and URL, the day answered and the primary source; url: the claim page; accessed: the day answered). APA and BibTeX forms are on the claim page.","why_not":{},"checked_by":{"sec-filing":"parsed from the SEC filing"}}}